| Clinical data | |
|---|---|
| Other names | 3-Methoxy-4-allyloxyphenethylamine; 4-Allyloxy-3-methoxyphenethylamine; ALLOMPEA; 3-Desmethoxyallylescaline |
| Routes of administration | Oral |
| Drug class | Psychoactive drug; "Mood elevator" |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C12H17NO2 |
| Molar mass | 207.273 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MAPEA, also known as 3-methoxy-4-allyloxyphenethylamine or as 3-desmethoxyallylescaline, is a psychoactive drug of the phenethylamine family related to the psychedelic drug and scaline allylescaline. It is the 3-desmethoxy analogue of allylescaline. The drug is said to be a "mood elevator" at doses of 100 to 300 mg orally, in contrast to related drugs like allylescaline which are psychedelic hallucinogens. The chemical synthesis of MAPEA has been described. MAPEA was first described in the scientific literature by Otakar Leminger in 1972. Subsequent, it was further described by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.